PE20190478A1 - Derivados de imidazol y su uso en el tratamiento de enfermedades inflamatorias o autoinmunes o canceres - Google Patents

Derivados de imidazol y su uso en el tratamiento de enfermedades inflamatorias o autoinmunes o canceres

Info

Publication number
PE20190478A1
PE20190478A1 PE2019000455A PE2019000455A PE20190478A1 PE 20190478 A1 PE20190478 A1 PE 20190478A1 PE 2019000455 A PE2019000455 A PE 2019000455A PE 2019000455 A PE2019000455 A PE 2019000455A PE 20190478 A1 PE20190478 A1 PE 20190478A1
Authority
PE
Peru
Prior art keywords
imidazol
treatment
autoimmune
inflammatory
cancer diseases
Prior art date
Application number
PE2019000455A
Other languages
English (en)
Inventor
Andrew Baxter
John Alexander Brown
David Hirst
Philip Humphreys
Katherine Louise Jones
Vipulkumar Kantibhai Patel
Original Assignee
Glaxosmithkline Intellectual Property N 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property N 2 Ltd filed Critical Glaxosmithkline Intellectual Property N 2 Ltd
Publication of PE20190478A1 publication Critical patent/PE20190478A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

Se refiere a derivados de imidazol, un compuesto de formula I o una sal del mismo en la que R2 es hidrogeno, alquilo C1-C6, alcoxi C1-C6, cicloalquilo C3-C7, entre otros; R3 puede ser halogeno, -CN, alquilo C1-3, alcoxi C1-3, -NO2, entre otros; a representa 0, 1 o 2. Son compuestos preferidos 5-(1H-imidazol-2-il)-1,3-dimetilpiridin-2(1H)-ona; 5-(4-bromo-1-etil-1h-imidazol-2-il)-1,3-dimetilpiridin-2(1H)-ona; 1,3-dimetil-5-(1-((tetrahidro-2H-piran-4-il)metil)-1H-imidazol-2-il)piridin-2(1H)-ona. Dicho compuesto modula la union a proteinas que contiene bromodominios como, por ejemplo, residuos de lisina acetilados y tienen utilidad en el tratamiento de enfermedades como artritis reumatoide y cancer.
PE2019000455A 2016-09-02 2017-08-31 Derivados de imidazol y su uso en el tratamiento de enfermedades inflamatorias o autoinmunes o canceres PE20190478A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1614934.6A GB201614934D0 (en) 2016-09-02 2016-09-02 Chemical compounds

Publications (1)

Publication Number Publication Date
PE20190478A1 true PE20190478A1 (es) 2019-04-04

Family

ID=57140084

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000455A PE20190478A1 (es) 2016-09-02 2017-08-31 Derivados de imidazol y su uso en el tratamiento de enfermedades inflamatorias o autoinmunes o canceres

Country Status (24)

Country Link
US (1) US20190175571A1 (es)
EP (1) EP3507283A1 (es)
JP (1) JP2019526577A (es)
KR (1) KR20190042701A (es)
CN (1) CN109790147A (es)
AR (1) AR109487A1 (es)
AU (1) AU2017317724A1 (es)
BR (1) BR112019004241A2 (es)
CA (1) CA3035312A1 (es)
CL (1) CL2019000538A1 (es)
CO (1) CO2019001871A2 (es)
CR (1) CR20190106A (es)
DO (1) DOP2019000047A (es)
EA (1) EA201990410A1 (es)
GB (1) GB201614934D0 (es)
JO (1) JOP20190029A1 (es)
MA (1) MA46085A (es)
MX (1) MX2019002491A (es)
PE (1) PE20190478A1 (es)
PH (1) PH12019500460A1 (es)
SG (1) SG11201901673SA (es)
TW (1) TW201817724A (es)
UY (1) UY37393A (es)
WO (1) WO2018041947A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20190101A (es) 2016-09-02 2019-07-04 Ironwood Pharmaceuticals Inc Estimuladores de sgc
CN111686107B (zh) * 2020-07-16 2021-06-08 中国农业科学院兰州兽医研究所 化合物plx51107用于制备预防或治疗非洲猪瘟药物的新用途
CN111588725B (zh) * 2020-07-16 2021-06-08 中国农业科学院兰州兽医研究所 化合物arv-825用于制备预防或治疗非洲猪瘟药物的新用途
CN111588721B (zh) * 2020-07-16 2021-06-08 中国农业科学院兰州兽医研究所 化合物zl0580用于制备预防或治疗非洲猪瘟药物的新用途
CN111686114B (zh) * 2020-07-16 2021-06-08 中国农业科学院兰州兽医研究所 化合物i-bet-762用于制备预防或治疗非洲猪瘟药物的新用途
WO2024018423A1 (en) * 2022-07-21 2024-01-25 Tay Therapeutics Limited Pyrroles and imidazoles as bet protein inhibitors
CN117257964B (zh) * 2023-10-25 2024-04-02 苏州大学 基于碳酸氢铵的微波诱导吲哚美辛原位无定形化增溶技术

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3406329A1 (de) * 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
DE4034060A1 (de) * 1990-10-26 1992-04-30 Basf Ag Biskationische azofarbstoffe
DE19809994B4 (de) * 1997-03-19 2006-02-09 Basf Ag Clathrate von Bis-[6-hydroxy-4-methyl-5-(3-methylimidazolium-1-yl)-3-(phen-4-ylazo)-pyridin-2-on]ethylen
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
PE20060285A1 (es) * 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
JP4388997B2 (ja) * 2006-09-05 2009-12-24 協和発酵キリン株式会社 イミダゾール誘導体
CN102015686B (zh) * 2008-03-21 2014-07-02 诺华股份有限公司 杂环化合物及其用途
CA2726588C (en) * 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CA2789474A1 (en) * 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
AU2013365926B9 (en) * 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
CN104788423B (zh) * 2015-03-13 2016-10-26 成都理工大学 一种新的囊性纤维化跨膜传导调节因子抑制剂
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds

Also Published As

Publication number Publication date
TW201817724A (zh) 2018-05-16
PH12019500460A1 (en) 2019-12-16
WO2018041947A1 (en) 2018-03-08
UY37393A (es) 2018-03-23
JOP20190029A1 (ar) 2019-02-25
JP2019526577A (ja) 2019-09-19
EP3507283A1 (en) 2019-07-10
US20190175571A1 (en) 2019-06-13
CL2019000538A1 (es) 2019-05-17
CO2019001871A2 (es) 2019-03-08
CA3035312A1 (en) 2018-03-08
EA201990410A1 (ru) 2019-09-30
MX2019002491A (es) 2019-07-08
SG11201901673SA (en) 2019-03-28
DOP2019000047A (es) 2019-03-15
GB201614934D0 (en) 2016-10-19
CN109790147A (zh) 2019-05-21
KR20190042701A (ko) 2019-04-24
AR109487A1 (es) 2018-12-12
CR20190106A (es) 2019-05-02
BR112019004241A2 (pt) 2019-06-04
MA46085A (fr) 2019-07-10
AU2017317724A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
PE20190478A1 (es) Derivados de imidazol y su uso en el tratamiento de enfermedades inflamatorias o autoinmunes o canceres
TR201911244T4 (tr) İmidazolonilkinolinler ve atm kinaz inhibitörleri olarak kullanımı.
PE20180508A1 (es) Amidas heterociclicas como inhibidores de quinasa
PE20160115A1 (es) Compuestos derivados de imidazol como inhibidores de protein quinasa
CY1122692T1 (el) Ενωσεις τετραϋδροπυραζολοπυριμιδινης
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
PE20181919A1 (es) Amidas heterociclicas utiles como moduladores de proteinas
PE20161073A1 (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
EA201792151A1 (ru) Новые 5-замещенные производные имидазола
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
PE20150218A1 (es) Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
MX2018004022A (es) Composiciones y metodos para unir dominios extracelulares de tipo i y tipo ii como proteinas quimericas heterologas.
MX354955B (es) Benzimidazoles y benzopirazoles sustituidos como antagonistas de ccr(4).
EA201891315A1 (ru) Твердые дисперсии, содержащие стимулятор sgc
AR091285A1 (es) Inhibidores de bromodominio y sus usos
PE20180032A1 (es) Compuestos quimicos
PE20161035A1 (es) Compuestos y usos de estos para la modulacion de la hemoglobina
PE20141974A1 (es) Compuestos de heterociclilo
EA201290600A1 (ru) Тиазольные и оксазольные ингибиторы киназы
AR095706A1 (es) Indazoles sustituidos con heteroarilo
AR089818A1 (es) Inhibidor de la quinasa que regula la señal de la apoptosis
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201390683A1 (ru) Пиперидинонкарбоксамидазаинданы - антагонисты рецептора cgrp
UY36033A (es) “inhibidores de diacilglicerol aciltransferasa 2”.
EA201691853A1 (ru) Агонисты мускариновых рецепторов